SEC Form 4 · accession 0001209191-18-000346
ACURA PHARMACEUTICALS, INC · ACUR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
CLAUDIUS LLC
Other
Period of report
Dec 14, 2017
Accepted (ET)
Jan 2, 2018 · 6:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000786947
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Dec 14, 2017 | S | 2,195,734 | $0.10 | D | 0 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold in a private transaction pursuant to a stock purchase agreement by and among Galen Partners III, LP ("Galen III"), Galen Employee Fund III, LP, ("Employee Fund") Galen Partners International III, LP ("Galen International") and several purchasers.
- F2The shares were sold as follows: 2,006,540 by Galen III, 180,928 by Galen International and 8,266 by Employee Fund.
- F3Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.